fbpx
QQQ
-1.91
368.39
-0.52%
DIA
-1.32
352.14
-0.38%
SPY
-2.11
442.76
-0.48%
TLT
+ 0.70
148.12
+ 0.47%
GLD
-1.36
172.53
-0.79%

Large Medical Cannabis Patient Study In Europe Picks African Company As Supplier

February 4, 2020 3:12 pm
Share to Linkedin Share to Twitter Share to Facebook Share to Print License More
Large Medical Cannabis Patient Study In Europe Picks African Company As Supplier

Drug Science (UK) has selected an African company as its supplier for its medical cannabis-focused clinical research initiative, Project Twenty21. The business in question: MG Health Limited, from the Kingdom of Lesotho.

According to the companies, Project Twenty21will target 20,000 U.K.-based patients suffering from chronic pain, anxiety disorder, epilepsy, multiple sclerosis, Post Traumatic Stress Disorder; substance use disorder and Tourette’s Syndrome. Researchers will look into the potential benefits of medical cannabis for the treatment of said conditions.

Francois Ferreira, COO of MG Health told Benzinga he thinks Project Twenty21 is a “bold initiative.” He noted his company sees this study as “a significant step toward collecting data from a large group of patients.

“This study will help validate the large body of anecdotal evidence regarding the therapeutic benefits of medical cannabis. We believe that our industry has an equally important role in helping to dispel some of the exaggerated claims and distracting myths surrounding the product,” he said.

See Also: 'A True Breakthrough': BOL Pharma Completes Medical Cannabis Export From Israel To UK

Adding to these comments, David Badcock, CEO of U.K.-based Drug Science explained Project Twenty21 does not offer a short-cut to accessing medical cannabis in the U.K.

“Patients will need to be seen by a physician, and provided their medical indication can be addressed by medical cannabis, and cannot be addressed with an existing treatment, the doctor may give the patient a prescription for medical cannabis,” he said.

Each individual prescription still needs to be approved by the Home Office, on a “single prescription per single patient” basis, before the pharmacy is allowed to source the product and dispense it to the patient.

Acknowledging this is “a very slow and cumbersome process,” he hopes access to cannabis products, when appropriate, “will become a little easier as Project T21 is able to provide feedback to the authorities and participating prescribers.”

For the latest in financial news, exclusive stories, memes follow Benzinga on Twitter, Facebook & Instagram. For the best interviews, stock market talk & videos, subscribe to Benzinga Podcasts and our YouTube channel.


Related Articles

Why Does Marijuana Make Some People Faint?

This article was originally published on The Fresh Toast, and appears here with permission. read more

The Parent Co. Sends 'Strong Signal' To Shareholders, Enters Into Lock-Up Agreements With Its Board And Leadership Team

TPCO Holding Corp. (NEO: GRAM) (OTCQX: GRAMF), which is doing business as The Parent Company, said Friday that both its leadership team and board of directors agreed to extend the share lock-up period for an additional six months. read more

How Nasdaq-Traded Hemp Co. Grove Inc. Became an Overnight Success and Why It's Positioned to Stay There

Grove Inc. (NASDAQ: GRVI) started as a group of hemp enthusiasts eager to spread the word about the benefits associated with the use of CBD and hemp-based products. Today, the company is on its way to becoming a leading global innovator in the wellness industry. read more

NBA Legend Allen Iverson Joins Al Harrington's Viola Cannabis Co. To 'Keep Pushing Boundaries'

Viola, the cannabis company founded and led by NBA veteran Al Harrington has welcomed another NBA star, Allen Iverson, to its ranks. The Philadelphia 76ers legend and Hall of Famer agreed to serve as the official talent partner for the Los Angeles cannabis brand. read more